en fr CN
  • Insights
  • Careers
  • Contact us

Median iCRO helps life sciences companies transform data into life-changing therapies. We understand what’s at stake for your business and offer unprecedented clinical trial imaging insights and expertise. Partnering with Pharma, Biotech, and CROs globally, we help improve business and patient outcomes.

Contact us
  • Pharmaceutical Research & Development Executives
  • Biotechnology Executives
  • Clinical Research Organizations

We transform medical images into meaningful, actionable insights to help better diagnose, treat, and monitor patients. We deploy proprietary artificial intelligence, computer vision, and signal processing technologies to develop imaging tests and services, addressing life-threatening unmet medical needs.

Contact us
  • Overview
  • Board of Directors & Management team
  • Shareholding structure
  • Stock market data
  • Analyst coverage
  • Financial agenda
  • Press releases
  • Corporate updates
  • Regulated documents
  • Investor contacts
  • Clinical Trials iCRO
  • About us
  • Clinical Trials iCRO
    • About iBiopsy®
    • Lung Cancer Screening
    • Liver Cancer – HCC
    • Liver Fibrosis – NAFLD/NASH
  • About us
  • Insights
  • Careers
    • Overview
    • Board of Directors & Management team
    • Shareholding structure
    • Stock market data
    • Analyst coverage
    • Financial agenda
    • Press releases
    • Corporate updates
    • Regulated documents
    • Investor contacts
    • Pharmaceutical Research & Development Executives
    • Biotechnology Executives
    • Clinical Research Organizations
  • Contact us

With iBiopsy® we are disrupting the management of serious diseases such as lung cancer, liver cancer, and NASH. We are deploying AI/ML Software as Medical Devices (SaMDs) to help health professionals diagnose patients earlier, treat them more effectively, and bring new hope. iBiopsy® is currently under development.

Contact us
  • About iBiopsy®
  • Lung Cancer Screening
  • Liver Cancer – HCC
  • Liver Fibrosis – NAFLD/NASH
Insights Case Studies

Case Studies

Keyword
  •  

    Median’s flexibility provides successful outcomes for an in-progress clinical trial

    Download MT-CS-Sample-Flexibility-v1.3.pdf
  •  

    Adapting analysis to expand eligibility inclusion

    Download MT-CS-Expand-Eligibility-Inclusion-v1.4.pdf
  •  

    Adapting a sponsor’s analysis protocol for improved accuracy and cost savings

    Download MT-CS-Adapting-Clients-Analysis-Protocol-v1.3.pdf
  • Newer Posts 1 2

Subscribe to receive email updates on our latest news and events.

Median Technologies collects and process the minimum relevant information to treat your query efficiently. To know more about how we store and process your personal data and about your rights, see our personal data protection policy.

Median Logo
Contact us
  • YouTube
  • Twitter
  • LinkedIn

© 2022 Median Technologies. All rights reserved.

  • Legal Notice
  • Data Protection Policy
  • Corporate Policy
  • Conventions conclues et avantages consentis

thinkerdoer